Celularity (CELU) Net Cash Flow (2019 - 2025)
Celularity (CELU) posted quarterly Net Cash Flow of $6.1 million for Q4 2025, up 846.9% year-over-year from $646000.0 in Q4 2024, and up 998.24% quarter-over-quarter from -$681000.0 in Q3 2025.
Celularity (CELU) Net Cash Flow (2019 - 2025) Analysis & Trends
Celularity (CELU) has reported Net Cash Flow for 7 consecutive years, with $6.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Cash Flow rose 846.9% year-over-year to $6.1 million; the TTM figure through Dec 2025 stood at $5.4 million (up 562.78% YoY), while the FY2025 annual figure was $5.4 million, up 562.78% from the prior year.
- Net Cash Flow improved to $6.1 million in Q4 2025 per CELU's latest filing, from -$681000.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $64.5 million in Q3 2021 and bottomed at -$35.4 million in Q4 2021.
- Historically, Net Cash Flow has averaged -$2.7 million across 5 years, with a median of -$1.0 million in 2024.
- Annual changes were most pronounced in 2021 — Net Cash Flow slumped 7520.18% — and 2025, when it soared 846.9%.
- Celularity's Net Cash Flow stood at -$35.4 million in 2021, then increased by 18.9% to -$28.7 million in 2022, then soared by 82.79% to -$4.9 million in 2023, then jumped by 113.09% to $646000.0 in 2024, then jumped by 846.9% to $6.1 million in 2025.
- Business Quant data shows CELU's Net Cash Flow at $6.1 million in Q4 2025, -$681000.0 in Q3 2025, and $632000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Celularity | 20.90 Mn | 14.72 Mn | -3.27 Mn | 6.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.12 Mn |
| Dec 31, 2025 | 6.12 Mn |
| Sep 30, 2025 | -681,000.00 |
| Sep 30, 2025 | -681,000.00 |
| Jun 30, 2025 | 632,000.00 |
| Jun 30, 2025 | 632,000.00 |
| Mar 31, 2025 | -673,000.00 |
| Mar 31, 2025 | -673,000.00 |
| Dec 31, 2024 | 646,000.00 |
| Dec 31, 2024 | 646,000.00 |
| Sep 30, 2024 | -223,000.00 |
| Sep 30, 2024 | -223,000.00 |
| Jun 30, 2024 | -1.39 Mn |
| Jun 30, 2024 | -1.39 Mn |
| Mar 31, 2024 | 1.79 Mn |
| Mar 31, 2024 | 1.79 Mn |
| Dec 31, 2023 | -4.94 Mn |
| Dec 31, 2023 | -4.94 Mn |
| Sep 30, 2023 | -2.81 Mn |
| Sep 30, 2023 | -2.81 Mn |